Effect of zinc tablets in the prevention of acute peripheral neuropathy in cancer patients treated with taxanes

Comparative study of the effect of 25 mg zinc tablets with placebo on the rate of prevention of acute peripheral neuropathy in cancer patients treated with taxanes

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200422047166N1

Enrollment

Registered

2020-06-10

Start date

2020-05-25

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug-induced polyneuropathy. Drug-induced polyneuropathy

Interventions

Intervention 1: Control group: Patients in the control group receive placebo capsule (25 mg) daily for two hours after lunch for 12 weeks. Intervention 2: Intervention group: Patients in the intervent

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cancer confirmed by biopsy and candidate for chemotherapy containing taxan Be able to give informed consent. The patient's performance status should be such that he or she can describe the condition.

Exclusion criteria

Exclusion criteria: They have diabetes, neurological disorders or neuropathy

Design outcomes

Primary

Measure	Time frame
Severity of neuropathy. Timepoint: Every 3 weeks for 3 months. Method of measurement: Criteria for side effects table.;Acute neuropathy. Timepoint: Every 3 weeks for 3 months. Method of measurement: Examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Haji Gholami

Esfahan University of Medical Sciences

Alihajigholami@med.mui.ac.ir+98 913 369 2567

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026